Our Pricing

The Science Behind Mounjaro UK NHS

Understanding the mounjaro uk nhs science explained helps patients make informed decisions about this groundbreaking weight loss treatment. Mounjaro (tirzepatide) represents a significant advancement in obesity medicine, being the first dual GIP/GLP-1 receptor agonist licensed by the MHRA in the UK. At Cured Pharmacy, we provide transparent access to Mounjaro from £135.00, supported by our UK-registered clinical team and superintendent pharmacist Tarun Kumar (GPhC 2233073).

How Mounjaro Works: The Dual Receptor Mechanism

Mounjaro contains tirzepatide, the first medication to simultaneously activate both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors [1]. This dual mechanism distinguishes it from single-pathway treatments like semaglutide (Wegovy) or liraglutide (Saxenda), which only target GLP-1 receptors.

The GLP-1 pathway reduces appetite by acting on brain regions that control satiety, whilst also slowing gastric emptying to prolong feelings of fullness after meals [1]. The GIP pathway complements this by improving insulin sensitivity and enhancing fat metabolism, creating a synergistic effect that produces greater weight reduction than either pathway alone [2].

In practical terms, patients typically notice reduced hunger, smaller portion sizes, and decreased cravings within the first few weeks of treatment. These effects are mediated by the medication's action on hypothalamic appetite centres and vagal nerve signalling, which communicate fullness signals from the gut to the brain [1].

Why Dual Activation Matters

The addition of GIP receptor activation addresses one of the limitations observed with GLP-1-only treatments. Whilst GLP-1 agonists effectively reduce appetite, the dual mechanism of tirzepatide appears to produce more substantial metabolic improvements, including better glycaemic control and greater fat mass reduction relative to lean mass preservation [2]. In the SURPASS-2 head-to-head trial, tirzepatide 15mg demonstrated superior weight loss compared to semaglutide 1mg, with patients achieving an average of 12.4kg versus 6.2kg reduction respectively over 40 weeks [3].

SURPASS Clinical Trial Programme: The Evidence Base

The SURPASS clinical trial programme comprises five phase 3 studies evaluating tirzepatide's efficacy and safety across diverse patient populations. SURPASS-1 through SURPASS-5 enrolled over 6,000 participants with type 2 diabetes, providing robust evidence for the medication's metabolic effects [3].

In SURPASS-3, participants receiving tirzepatide 15mg (the highest licensed dose) achieved an average body weight reduction of 13.9kg (approximately 15% of baseline weight) over 52 weeks, compared to 7.8kg with insulin degludec [3]. Importantly, these results were achieved alongside improvements in HbA1c, blood pressure, and lipid profiles, demonstrating comprehensive cardiometabolic benefits.

The SURMOUNT-1 trial specifically examined tirzepatide in patients without diabetes but with obesity or overweight plus weight-related complications. Participants on the 15mg dose achieved an average 22.5% body weight reduction over 72 weeks — one of the highest reductions observed in any obesity pharmacotherapy trial to date [4]. These findings directly informed the MHRA's decision to license Mounjaro for weight management in the UK.

Mounjaro UK NHS Approval and Prescribing Criteria

The MHRA licensed Mounjaro for weight management in the UK in November 2023, following comprehensive review of the SURMOUNT trial data. NICE subsequently evaluated tirzepatide for potential NHS commissioning, though availability through NHS services remains limited due to budget constraints and capacity considerations [5].

Current prescribing criteria in the UK typically require a BMI of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or obstructive sleep apnoea. All patients must demonstrate commitment to lifestyle modifications including dietary changes and increased physical activity [5].

At Cured Pharmacy, our UK-registered prescribers assess eligibility during a free online consultation lasting under three minutes. This assessment evaluates your medical history, current medications, contraindications, and suitability for tirzepatide therapy. Mounjaro is a prescription-only medication and cannot be supplied without clinical approval from a UK prescriber.

NHS vs Private Prescription Access

Whilst Mounjaro holds UK marketing authorisation, NHS prescription availability varies significantly by region and clinical commissioning group. Many patients access tirzepatide through private prescription services, which offer shorter waiting times and consistent supply. Cured Pharmacy provides transparent upfront pricing from £135.00, with the final cost determined by your prescribed dose strength following clinical assessment.

Comparing Mounjaro to Other Weight Loss Treatments

Understanding how Mounjaro compares to alternatives helps patients and prescribers select the most appropriate treatment. Wegovy (semaglutide) remains the most established GLP-1 receptor agonist for weight management in the UK, with robust evidence from the STEP trial programme showing average weight reductions of 14.9% over 68 weeks [6].

Saxenda (liraglutide) represents an earlier-generation GLP-1 agonist requiring daily injection rather than weekly administration. Clinical trials demonstrated average weight loss of 8-9% over 56 weeks, which is lower than the newer weekly injectable options but still clinically meaningful for many patients [6].

Orlistat-based treatments (including Xenical, Alli, and Orlos) work through a completely different mechanism — blocking fat absorption in the intestine rather than affecting appetite hormones. These medications suit patients who prefer oral tablets over injections, though average weight loss is typically more modest at 5-7% of baseline weight [7].

Dosing Schedule and Treatment Progression

Mounjaro follows a structured dose escalation schedule designed to minimise gastrointestinal side effects whilst optimising therapeutic response. Treatment begins at 2.5mg once weekly for the first four weeks, serving as an initial tolerability dose rather than a therapeutic dose [1].

After four weeks, the dose increases to 5mg weekly, which represents the minimum therapeutic dose for weight management. Depending on individual response and tolerability, your prescriber may recommend further increases to 7.5mg, 10mg, 12.5mg, or the maximum licensed dose of 15mg weekly [1]. Each dose escalation occurs at four-week intervals, allowing your body to adapt gradually.

The KwikPen delivery device contains four pre-filled doses, administered subcutaneously (under the skin) in the abdomen, thigh, or upper arm. Injection technique is straightforward, and our clinical team provides comprehensive guidance during your consultation. Consistent weekly administration on the same day optimises steady-state drug levels and treatment efficacy.

Expected Timeline for Results

Most patients notice appetite reduction within the first 1-2 weeks of starting Mounjaro, though measurable weight loss typically becomes apparent after 4-8 weeks as the dose escalates to therapeutic levels [4]. Clinical trials showed progressive weight reduction continuing through 72 weeks, with the greatest rate of loss occurring in the first 20-36 weeks of treatment. Your UK prescriber will monitor progress through regular follow-up assessments to ensure safe and effective treatment progression.

Safety Profile and Common Side Effects

The most frequently reported side effects of Mounjaro are gastrointestinal in nature, including nausea, diarrhoea, decreased appetite, vomiting, constipation, and abdominal discomfort. These effects are typically mild to moderate in severity and tend to diminish as treatment continues [1][4].

In the SURMOUNT-1 trial, nausea occurred in approximately 33% of participants on the 15mg dose, though fewer than 5% discontinued treatment due to gastrointestinal side effects [4]. Starting at a low dose and escalating gradually significantly reduces the likelihood and severity of these symptoms.

More serious but rare risks include pancreatitis, gallbladder disease, and thyroid C-cell tumours (observed in rodent studies but not confirmed in humans). Mounjaro is contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 [1]. Your UK prescriber will screen for these contraindications during your clinical assessment.

Hypoglycaemia (low blood sugar) is uncommon with Mounjaro monotherapy but may occur if combined with other diabetes medications such as insulin or sulfonylureas. Regular monitoring and medication adjustments under prescriber supervision help mitigate this risk. All prescription medications carry potential side effects, and our clinical team at Cured Pharmacy ensures you receive comprehensive safety information before starting treatment.

Scientific References

1. Electronic Medicines Compendium. (2024). Mounjaro 2.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC). Retrieved from https://www.medicines.org.uk/emc/product/14298
2. Frias, J. P., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519
3. Ludvik, B., et al. (2021). Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet, 398(10300), 583–598. https://doi.org/10.1016/S0140-6736(21)01443-4
4. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
5. National Institute for Health and Care Excellence. (2023). Tirzepatide for treating type 2 diabetes [TA924]. Retrieved from https://www.nice.org.uk/guidance/ta924
6. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
7. Torgerson, J. S., et al. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Mounjaro (tirzepatide) is a prescription-only medicine in the UK and cannot be supplied without approval from a registered clinician following a full medical assessment.